Orphan Drugs Asia Live: Customisation for APAC beyond the extension of US

In Orphan Drug Congress, Orphan Drugs Live by rachel

Why customisation for Asia Pacific (APAC)? Cynthia Loo, Asia Pacific Executive Director of BioMarin highlighted the need to have a customised policies for APAC.

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. BioMarin has developed and commercialized five products since 1997, a remarkable accomplishment in the biopharmaceutical industry, and a testament to the company’s passion and dedication to patients with serious unmet medical needs.

The APAC market is vastly different from our US and Europe counterparts as APAC’  is a constantly evolving market, especially in healthcare and reimbursement.  Hence there is a pressing need for APAC to customise it’s own biopharmaceutical profile, with lessons leearnt from US and Europe. As the orphan drug sales is projected to hit 127B in 2018, more has to be done to improve market planning and timing to reduce drug lag.

Establishing presence in APAC market will require the following:

•Customization for each country based on political, economical and regulatory environments
•Model should be flexible to allow continual evolvement due to external or internal changes